Hematologic Diseases


patient and staff

The primary goal of the hematologic diseases program is to develop new treatment strategies for hematologic malignancies, the most frequent cancer type in pediatrics. Although cure rates are excellent for many subtypes of childhood leukemia and lymphoma, new approaches are needed to overcome resistance to standard therapies and to decrease treatment-associated sequelae in survivors of pediatric cancer. We conduct collaborative pre-clinical, translational, and clinical studies that focus on developing targeted agents and applying immunotherapy to direct anti-tumor responses for childhood leukemias and lymphomas.

pob hematologic team 2011

Current activities include:

  •  Development of anti-CD19 and anti-CD22 chimeric antigen receptor (CAR) therapy and other targeted agents and immune-based therapies
  • Novel approaches to hematopoietic stem cell transplantation, with a focus on immune restoration and treatment of patients with primary immune deficienies
  • Post-transplant allogeneic immunotherapy to direct anti-tumor responses and treatment of relapse after transplant
  • Pre-clinical studies designed to support current and future translational trials, to apply new methods in the study of cellular, molecular, genetic, and genomic biology, and to probe for new therapeutic targets                    

Collaborative studies include:

  • Neurotoxicity of CAR and other novel immunotherapies
  • Education of minors who donate stem cells

Physicians


Nurse Practitioners

  • Bonnie Yates, CPNP

Research Nurses

  • Cindy Delbrook, RN

Data Managers

  • Ekaterina Nikitina
  • Showri Kakumanu

Clinic Coordinator

  • Terri Moore